Abstract: The invention provides bispecific antibodies binding to human carcinoembryonic antigen CEACAM5 and human CD47, polynucleotides encoding such bispecific antibodies and vectors and host cells comprising such polynucleotides. The invention further provides methods for selecting and producing such antibodies and methods of using such antibodies in the treatment of diseases in monotherapy as well in combination.
Type:
Application
Filed:
December 8, 2022
Publication date:
March 14, 2024
Applicant:
LamKap Bio beta Ltd.
Inventors:
Vanessa BUATOIS, Sara MAJOCCHI, Klaus STREIN
Abstract: The invention provides bispecific antibodies binding to human carcinoembryonic antigen CEACAM5 and human CD47, polynucleotides encoding such bispecific antibodies and vectors and host cells comprising such polynucleotides. The invention further provides methods for selecting and producing such antibodies and methods of using such antibodies in the treatment of diseases in monotherapy as well in combination.
Type:
Grant
Filed:
May 31, 2019
Date of Patent:
January 17, 2023
Assignee:
LamKap Bio beta Ltd.
Inventors:
Vanessa Buatois, Stefano Majocchi, Klaus Strein
Abstract: The invention provides bispecific antibodies binding to human carcinoembryonic antigen CEACAM5 and human CD47, polynucleotides encoding such bispecific antibodies and vectors and host cells comprising such polynucleotides. The invention further provides methods for selecting and producing such antibodies and methods of using such antibodies in the treatment of diseases in monotherapy as well in combination.
Type:
Application
Filed:
May 31, 2019
Publication date:
April 23, 2020
Applicant:
LamKap Bio beta Ltd.
Inventors:
Vanessa BUATOIS, Stefano MAJOCCHI, Klaus STREIN